Allmed Medical(SZ:002950)2025-01-24 10:25Financial Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between RMB 305 million and RMB 355 million, representing an increase of 176.27% to 221.56% compared to the previous year's profit of RMB 110.4 million[3]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between RMB 303 million and RMB 335 million, reflecting an increase of 96.16% to 116.88% from RMB 154.5 million in the previous year[3]. - The basic earnings per share is expected to be between RMB 0.49 and RMB 0.57, compared to RMB 0.17 in the previous year[3]. Operational Performance - The company has implemented advanced production capacity and technology upgrades, contributing to an increase in market share for traditional products and sales growth in functional dressings[6]. - In 2023, the company recognized impairment losses totaling RMB 102.56 million, resulting in a lower performance base for 2024[6]. Compliance and Reporting - The performance forecast is based on preliminary calculations and has not been audited by the accounting firm, with final figures to be disclosed in the 2024 annual report[5][7]. - The company is committed to strict compliance with relevant laws and regulations regarding information disclosure, urging investors to make cautious decisions[7].